Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Wilbert Matthews"'
Publikováno v:
The Journal of Thoracic and Cardiovascular Surgery. 107:43-49
Tumor necrosis factor can alter the cell cycle of tumor cells and protect hematopoietic stem cells from cell cycle-specific chemotherapy, but the ability of tumor necrosis factor to protect cancer cells from chemotherapy by manipulation of the cell c
Autor:
Andrea Abati, Maria Tsokos, Patricia Fetsch, Emily J. Stevens, Herbert K. Oie, Daphne J. Y. Mew, Wilbert Matthews, Harvey I. Pass, Helen W. Pogrebniak
Publikováno v:
The Annals of thoracic surgery. 59(4)
This report characterizes nine new cell lines derived from patients with malignant pleural mesothelioma. The lines were initiated between July 1990 and July 1992 from solid tumors (5 lines) or effusions (4 lines) and had proliferated for a period of
Publikováno v:
SPIE Proceedings.
The ability of photodynamic therapy (PDT) to activate macrophages and produce cytokines, specifically tumor necrosis factor (TNF), is unknown. Three day thioglycolate elicited macrophages were incubated with 25 ug/mi Photofrin II (P11) for 2 hour, af
Autor:
Steven Evans, Douglas L. Fraker, Jeffrey A. Norton, Wilbert Matthews, Roger R. Perry, Havey I. Pass
Publikováno v:
Journal of the National Cancer Institute. 82(1)
Photodynamic therapy (PDT) involves the treatment of tumors in the presence of sensitizer, light, and oxygen, causing energy-dependent cytotoxicity. A vascular effect that causes hemorrhagic tumor necrosis has been described with PDT, but its basis r
Autor:
Wilbert Matthews, James B. Mitchell, Roger R. Perry, Harvey I. Pass, John A. Cook, Steven Evans
Publikováno v:
Lung Cancer. 6:63
The influence of light dose-rate delivery was studied in human lung adenocarcinoma A549 cells treated with hematoporphyrin derivative (Photofrin II)-based photodynamic therapy. Clonogenic cell survival curves were generated for cells treated for 2 h
Autor:
Wilbert Matthews, Paul H. Sugarbaker
Publikováno v:
Oncology. 42:377-383
In the past, most work in tumor immunology involved attempts to demonstrate tumor-specific transplantation antigens; however, recent in vitro work has shown that it is not necessary to sensitize to a specific tumor antigen to achieve lysis of syngeni
Autor:
N. Nakissa, Louis S. Constine, Wilbert Matthews, P. Rubin, K. Klinga, Manfred Volm, Luigi Di Lauro, Ken Koshiba, Paul H. Sugarbaker, Jürgen Mattern, Veli-Matti Wasenius, Bonaventura Lazzaro, Wolfram Domschke, Joseph P. Fanning, R. Strohl, James M. Slater, P. Brockmann, James D. Kettering, Eiichi Furusawa, Robert Burns, Daila S. Gridley, Masayuki Saito, S. Domschke, Leila Risteli, Juha Risteli, Robert L. Nutter, S. Furusawa, David W. Mantik, Frej Stenbäck, Massimo Lopez, Ch. Ell, H.J. König, Hideki Ohtani, Richard S. Porensky, Delvyn C. Case, Paola Papaldo, Benno Runnebaum
Publikováno v:
Oncology. 42:I-V
Publikováno v:
Cancer. 31:175-179
Serum alkaline ribonuclease (SRNase) levels were determined in 49 normal adults and 94 patients with clinically operable malignancies. The mean SRNase levels were higher in 22 patients with adenocarcinomas (P < .003) and 28 patients with squamous car
Autor:
Paul H. Sugarbaker, Wilbert Matthews
Publikováno v:
Cellular immunology. 57(1)
Irradiated BALB/c spleen-cell populations actively cytotoxic to BL/6 alloantigens (modulator cells) were capable of suppression of the in vitro generation of BALB/c anti-BL/6 cellular cytotoxicity. This suppression was abrogated by anti-θ serum plus
Autor:
Paul H. Sugarbaker, Wilbert Matthews
Publikováno v:
Cellular immunology. 57(1)
Previous reports have suggested that repeated alloantigenic challenge increases humoral responses to alloantigens, but may cause decreasing cellular responses. We stimulated BALB/c (H-2 d ) mice with intraperitoneal EL-4 tumor (H-2 b ) and serially a